Table 3 STC2 mediates tumour cells’ resistance to therapies
From: Stanniocalcin 2 (STC2): a universal tumour biomarker and a potential therapeutical target
Treatments | Tumours | Drug | Biological functions of STC2 | References |
|---|---|---|---|---|
Chemotherapy | ||||
| Â | Colorectal cancer | Bevacizumab (Anti-VEGF) | Promotes cell proliferation and migration due to reduced oxygen levels | [161] |
| Â | Cervical cancer | Cisplatin | Promotes cell proliferation Facilitates the activation of MAPK signaling pathway | [150] |
| Â | Colorectal cancer | Oxaliplatin | Compromises apoptosis Activates the PI3K-Akt signaling to upregulate P-glycoprotein | [151] |
| Â | HCC | Paclitaxel | Upregulates the expression of pro-survival proteins like P-glycoprotein and Bcl-2 that enhance cell viability | [162] |
| Â | Lung adenocarcinoma | EGFR TKI | Activates the Jun-Axl-Erk signaling to enhance cell survival | [43] |
Radiotherapy | ||||
|  | Nasopharyngeal carcinoma | ‒ | Promotes colony formation Suppresses apoptosis Drives cell cycle progression from G1 to S phase Enhances migratory and invasive ability of tumour cells | |